Oxaliplatin

...some 6,000 people a year in the UK. Pharmaceutical giant Roche offered a patient access scheme to reduce the cost of Avastin, which would have seen a cap on its cost at 12 months and free oxaliplatin. Roche said this would have reduced the...

In this article: Cancer, Bevacizumab, UK, Department of Health, Surgery, and Capecitabine

...drugs intravenously (bevacizumab at 10 milligrams per kilogram, followed by gemcitabine at 1,000 milligrams per square meter, and oxaliplatin at 85 milligrams per square meter) on days 1 and 15, every 28 days. Whole-body PET scans were...

In this article: Cancer, Gemcitabine, Bevacizumab, and Peripheral neuropathy

...the Israeli company. Teva's North American sales rose 33 percent to $2.23 billion due to the introduction of a generic version of Ortho Tri-Cyclen birth control and a generic version of the cancer treatment Eloxatin. Other generic drugs...

In this article: Teva Pharmaceutical Industries Ltd., Thomson Reuters, Legal age, Eloxatin, Lotrel, Cancer, Multiple sclerosis, Copaxone, and North Wales

...the way we run clinical trials in cancer patients." Based on the trial the US Food and Drug Administration approved a new agent, oxaliplatin, administered with 5-fluorouracil for the indication "treatment of previously untreated...

In this article: Cancer, Pharmacia, Canada, U.S., Medical advice, Surgery, and 5-fluorouracil

...development. "Our updated proof-of-concept Phase 2 safety and efficacy results continue to suggest that picoplatin could be superior to oxaliplatin as a neuropathy-sparing alternative when used in combination as a first-line treatment for...

In this article: Cancer, Platinum, Neuropathy, 5-fluorouracil, FDA, Medical advice, and Thrombocytopenia

...known as FOLFOX for the treatment of colorectal cancer. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin or by Medac GmbH under the trademark Oxaliplatin Medac. There are generic equivalents on the market now

In this article: Cancer, Platinum, Fluorouracil, Trademark, Cisplatin, Carboplatin, U.S. Food and Drug Administration, Sanofi-Aventis, and Folinic acid

...colon cancer. The appeals court ruling Thursday sends the case back to U.S. District Court for further consideration on Eloxatin, which generated annual U.S. sales of more than $1.3 billion last year for the French company. Israeli-based...

In this article: Sanofi-Aventis, U.S., Legal age, Sanofi pasteur, Eloxatin, Cancer, Teva Pharmaceutical Industries Ltd., and U.S. Food and Drug Administration

...showed that Vectibix significantly improved progression-free survival in mCRC patients with KRAS wild-type tumors in combination with FOLFOX (an oxaliplatin-based chemotherapy). Detailed efficacy and safety data from both studies will be...

In this article: KRAS, Vectibix, Cancer, Amgen, FDA, Irinotecan, Chemotherapy regimens, Medical advice, SEC, and Joint venture

...the duration of their prior therapy. EZN-2208 is being evaluated in a Phase 2 study in patients with metastatic colorectal cancer who failed prior oxaliplatin and irinotecan containing regimens (CRC). EZN-3042, a novel survivin messenger...

In this article: Cancer, Oligonucleotide, Irinotecan, Androgen, Revenue, Locked nucleic acid, G-CSF, and Docetaxel